All Stories

  1. Memory experiences under psychedelics – an exploratory prospective online study
  2. Actions speak louder than words: Towards measuring real-world behaviour change in psychedelic research
  3. Psychedelics and women’s mental health: the effects of female sex hormones on psychedelics’ efficacy and tolerability
  4. Subjective and neurocognitive profiling of clinical doses of 3,4-methylenedioxymethamphetamine (MDMA) in healthy volunteers: implications for therapeutic use
  5. Comparative effects of ayahuasca and breathwork on self-reported cognitive flexibility, emotion regulation, positive affect, and sleep quality
  6. Between Enhancement and Risk: A Critical Review of Psychedelic Microdosing
  7. Use of psychedelic treatments in psychiatric clinical practice: an EPA policy paper
  8. Safety and cognitive pharmacodynamics following dose escalations with 3-methylmethcathinone (3-MMC): a first in human, designer drug study
  9. Inter-individual variability in neural response to low doses of LSD
  10. Self-Rated Effectiveness of Ayahuasca and Breathwork on Well-Being, Psychological Resilience, Self-Compassion, and Personality: An Observational Comparison Study
  11. Effects of psychedelic microdosing versus conventional ADHD medication use on emotion regulation, empathy, and ADHD symptoms in adults with severe ADHD symptoms: A naturalistic prospective comparison study
  12. A Preliminary Inventory of Kratom (Mitragyna Speciosa) Products and Vendors on the Darknet and Cryptomarkets
  13. Assessment of the Acute Effects of 2C‐B vs. Psilocybin on Subjective Experience, Mood, and Cognition
  14. Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: Findings from the Global Drug Survey 2020
  15. Assessment of the acute effects of 2C-B vs psilocybin on subjective experience, mood and cognition
  16. Psilocybin induces acute and persisting alterations in immune status and the stress response in healthy volunteers
  17. Microdosing with psychedelics to self-medicate for ADHD symptoms in adults: A prospective naturalistic study
  18. A systematic review of (pre)clinical studies on the therapeutic potential and safety profile of kratom in humans
  19. Spontaneous and deliberate creative cognition during and after psilocybin exposure
  20. Exploring the use of Kratom (Mitragyna speciosa) via the YouTube data tool: A novel netnographic analysis
  21. A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers
  22. Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin
  23. The therapeutic potential of microdosing psychedelics in depression
  24. Motives for Classical and Novel Psychoactive Substances Use in Psychedelic Polydrug Users
  25. Microdosing psychedelics: More questions than answers? An overview and suggestions for future research
  26. Psychedelic medicine: The biology underlying the persisting psychedelic effects
  27. Sub-Acute Effects of Psilocybin on Empathy, Creative Thinking, and Subjective Well-Being
  28. A First-in-Man Study with 4-Fluoroamphetamine Demonstrates it Produces a Mild Psychedelic State
  29. Increased Temporal Discounting in Social Anxiety Disorder Normalizes after Oxytocin Treatment
  30. Independent elevation of peripheral oxytocin concentrations and reduction in cognitive empathy during 4-fluoroamphetamine intoxication
  31. Sub-acute and long-term effects of ayahuasca on affect and cognitive thinking style and their association with ego dissolution
  32. Safety Profile and Neurocognitive Function Following Acute 4-Fluoroamphetamine (4-FA) Administration in Humans
  33. A single dose of cocaine enhances prospective memory performance
  34. Self-medication with psychedelics for mental or physical problems occurs amongst psychedelic users
  35. Intoxicated aggression: Do alcohol and stimulants cause dose-related aggression? A review
  36. Out of the box: A psychedelic model to study the creative mind
  37. Drug liking and wanting, not impulsive action or reflection is increased by 4-fluoroamphetamine
  38. Depressive mood ratings are reduced by MDMA in female polydrug ecstasy users homozygous for the l-allele of the serotonin transporter
  39. Neurocognition and subjective experience following acute doses of the synthetic cannabinoid JWH‐018: a phase 1, placebo‐controlled, pilot study
  40. Peripheral endocannabinoid concentrations are not associated with verbal memory impairment during MDMA intoxication
  41. Emotional Empathic Responses to Dynamic Negative Affective Stimuli Is Gender-Dependent
  42. Erratum to: MDMA-induced indifference to negative sounds is mediated by the 5-HT2A receptor
  43. MDMA-induced indifference to negative sounds is mediated by the 5-HT2A receptor
  44. MDMA-Induced Dissociative State not Mediated by the 5-HT2A Receptor
  45. Multifaceted empathy of healthy volunteers after single doses of MDMA: A pooled sample of placebo-controlled studies
  46. A pooled analysis of on-the-road highway driving studies in actual traffic measuring standard deviation of lateral position (i.e., “weaving”) while driving at a blood alcohol concentration of 0.5 g/L
  47. Neurocognitive performance following acute mephedrone administration, with and without alcohol
  48. Ayahuasca enhances creative divergent thinking while decreasing conventional convergent thinking
  49. Subjective aggression during alcohol and cannabis intoxication before and after aggression exposure
  50. Cannabis and tolerance: acute drug impairment as a function of cannabis use history
  51. Verbal Memory Impairment in Polydrug Ecstasy Users: A Clinical Perspective
  52. Brain reactivity to alcohol and cannabis marketing during sobriety and intoxication
  53. Cannabis and cocaine decrease cognitive impulse control and functional corticostriatal connectivity in drug users with low activity DBH genotypes
  54. Emotion recognition during cocaine intoxication
  55. MDMA, cannabis, and cocaine produce acute dissociative symptoms
  56. Psychedelic symptoms of cannabis and cocaine use as a function of trait impulsivity
  57. Changes in serotonin transporter (5-HTT) gene expression in peripheral blood cells after MDMA intake
  58. Memory and mood during MDMA intoxication, with and without memantine pretreatment
  59. Rivastigmine but not vardenafil reverses cannabis-induced impairment of verbal memory in healthy humans
  60. No Evidence that MDMA-Induced Enhancement of Emotional Empathy Is Related to Peripheral Oxytocin Levels or 5-HT1a Receptor Activation
  61. Single doses of THC and cocaine decrease proficiency of impulse control in heavy cannabis users
  62. Escitalopram Decreases Cross-Regional Functional Connectivity within the Default-Mode Network
  63. Methylphenidate reduces functional connectivity of nucleus accumbens in brain reward circuit
  64. Inhibition of MDMA-induced increase in cortisol does not prevent acute impairment of verbal memory
  65. Psychomotor Function in Chronic Daily Cannabis Smokers during Sustained Abstinence
  66. A Case-Control Study Estimating Accident Risk for Alcohol, Medicines and Illegal Drugs
  67. Medicinal Δ9-tetrahydrocannabinol (dronabinol) impairs on-the-road driving performance of occasional and heavy cannabis users but is not detected in Standard Field Sobriety Tests
  68. Effects of Acute MDMA Intoxication on Mood and Impulsivity: Role of the 5-HT2 and 5-HT1 Receptors
  69. Effects of stimulant drugs on actual and simulated driving: perspectives from four experimental studies conducted as part of the DRUID research consortium
  70. A placebo-controlled study to assess Standardized Field Sobriety Tests performance during alcohol and cannabis intoxication in heavy cannabis users and accuracy of point of collection testing devices for detecting THC in oral fluid
  71. MDMA (ecstasy) effects on actual driving performance before and after sleep deprivation, as function of dose and concentration in blood and oral fluid
  72. MDMA intoxication and verbal memory performance: a placebo-controlled pharmaco-MRI study
  73. Blockade of 5-HT2 Receptor Selectively Prevents MDMA-Induced Verbal Memory Impairment
  74. Dose-related effects of MDMA on psychomotor function and mood before, during, and after a night of sleep loss
  75. Erratum: Involvement of Inferior Parietal Lobules in Prospective Memory Impairment During Acute MDMA (Ecstasy) Intoxication: An Event-Related fMRI Study
  76. Involvement of Inferior Parietal Lobules in Prospective Memory Impairment during Acute MDMA (Ecstasy) Intoxication: An Event-Related fMRI Study
  77. Memory and mood during the night and in the morning after repeated evening doses of MDMA
  78. Sustained attention and serotonin: a pharmaco-fMRI study
  79. Acute effects of nocturnal doses of MDMA on measures of impulsivity and psychomotor performance throughout the night
  80. The role of 5-HT1a and 5-HT2a receptors in attention and motor control: a mechanistic study in healthy volunteers
  81. Stimulant effects of 3,4-methylenedioxymethamphetamine (MDMA) 75 mg and methylphenidate 20 mg on actual driving during intoxication and withdrawal
  82. Selective verbal and spatial memory impairment after 5-HT1A and 5-HT2A receptor blockade in healthy volunteers pre-treated with an SSRI
  83. MDMA and alcohol effects, combined and alone, on objective and subjective measures of actual driving performance and psychomotor function
  84. Acute dose of MDMA (75 mg) impairs spatial memory for location but leaves contextual processing of visuospatial information unaffected
  85. Transient memory impairment after acute dose of 75mg 3.4-Methylene-dioxymethamphetamine
  86. A combined neurophysiological and behavioural study into the stimulating effects of fexofenadine on performance
  87. Acute Effects of 3,4-Methylenedioxymethamphetamine (MDMA) on Behavioral Measures of Impulsivity: Alone and in Combination with Alcohol